Immunotherapy drug nivolumab ruled too costly for head and neck cancer patients - Belfast Telegraph

Belfast Telegraph

Immunotherapy drug nivolumab ruled too costly for head and neck cancer patients Belfast Telegraph Professor Kevin Harrington, from the Institute of Cancer Research, London, who led the UK arm of a Phase III trial looking at treating head and neck cancers with nivolumab, said: " It is disappointing and frustrating that today's decision means doctors ... Nivolumab not recommend for relapsed or metastatic head-and-neck cancer on the NHSThe Institute of Cancer Research all 2 news articles »

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2p13G6w
via IFTTT